Algernon Pharmaceuticals’ NP-120 (Ifenprodil) Outperforms Merck’s Phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110%

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement